SCHEMBL2837797

SCHEMBL2837797

C#CCCOC(=O)c1cccc(F)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 1/20 0.47
CES1 P23141 1/20 0.47
NPC1 O15118 2/20 0.47
TDP1 Q9NUW8 2/20 0.47
ADRB2 P07550 1/20 0.47
ADRB1 P08588 1/20 0.47
ADRB3 P13945 1/20 0.47
RAB9A P51151 1/20 0.47
PTPN2 P17706 1/20 0.46
PTPN1 P18031 1/20 0.46
PTPN6 P29350 1/20 0.46
PTPN11 Q06124 1/20 0.46
FNTA P49354 1/20 0.46
FNTB P49356 1/20 0.46
ESR1 P03372 1/20 0.46
ESR2 Q92731 1/20 0.46
PARP1 P09874 1/20 0.45
PKM P14618 1/20 0.44
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2835264 0.91 PTPN2 (0.49) CES2CES1NPC1TDP1ADRB2
SCHEMBL2830659 0.90 PTPN2 (0.53) CES2CES1NPC1TDP1ADRB2
SCHEMBL2832878 0.86 NPC1 (0.54) CES2CES1NPC1TDP1ADRB2
SCHEMBL2834690 0.81 CA12 (0.46) CES2CES1TDP1ADRB2ADRB1
SCHEMBL576722 0.80 TDP1 (0.63) NPC1TDP1RAB9AFNTAFNTB
SCHEMBL11354226 0.80 CES2 (0.52) CES2CES1NPC1TDP1ADRB2
SCHEMBL28953541 0.80 CES2 (0.52) CES2CES1NPC1TDP1ADRB2
SCHEMBL2834373 0.80 KMT2A (0.50) CES2CES1NPC1RAB9AFNTA
SCHEMBL522694 0.80 LMNA (0.64) CES2CES1NPC1TDP1ADRB2
SCHEMBL18746585 0.78 MEN1 (0.50) NPC1TDP1RAB9AFNTAFNTB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8263268-B2 Ester compound, and non-aqueous electrolyte solution and lithium secondary battery each using the ester compound UBE INDUSTRIES, LTD. (JP) 2012-09-11 US disclosed
EP-2108640-B1 ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND UBE INDUSTRIES (JP) 2012-07-25 EP disclosed
US-20100119955-A1 ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND UBE INDUSTRIES, LTD. (JP) 2010-05-13 US disclosed
EP-2108640-A1 ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND Ube Industries, Ltd. (JP) 2009-10-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100119955-A1 ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND CEL, LAGE3, PEF1 CES2 87/4885CES1 994/4885NPC1 962/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.